Physician profile
Michael R Keller
NPI 1821062183
$1,401.69
in general payments reported to CMS, 2019-2025
20 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2021: $90.37 · 2022: $229 · 2023: $280 · 2024: $333 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $333.83 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $145.60 | 2019-2022 | |
| Shockwave Medical, INC | $128.60 | 2022 | |
| Corcept Therapeutics | $89.99 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $78.09 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Inspire Medical Systems, INC. | $73.72 | 2024 | Inspire |
| Abbott Laboratories | $67.38 | 2024-2025 | Freestyle Libre 3 |
| Optinose US, INC. | $65.12 | 2022 | |
| Glaxosmithkline, LLC. | $60.15 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $57.60 | 2024 | Rexulti |
| Shield Therapeutics INC | $57.47 | 2023-2024 | Accrufer |
| Eisai INC. | $39.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $39.06 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.77 | 2023 | |
| Lilly USA, LLC | $30.04 | 2025 | Kisunla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $29.64 | 2024-2025 | Zoryve |
| Bioventus LLC | $23.68 | 2023 | Durolane |
| Abbvie INC. | $22.37 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $14.58 | 2022 | |
| Amgen INC. | $14.21 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.